Skip to main content

Security report for janssen.com

Innovative Medicine Global · Healthcare · N/a

Low risk. 2 critical or high findings in SSL/TLS.

Security score

80/100

Risk levelLow

0–100, higher is better. How it is calculated

Johnson & Johnson Innovative Medicine is a division of the multinational healthcare giant Johnson & Johnson, focusing on pharmaceutical research and development of innovative medicines. The website serves as a professional platform targeting healthcare professionals, researchers, and stakeholders, providing information about their commitment to advancing healthcare solutions globally. The site demonstrates a mature digital presence with modern web technologies, including Google Tag Manager for analytics and OneTrust for cookie consent management. The technical infrastructure is robust, with good mobile optimization and accessibility features, although some security headers are not explicitly detected in the provided content. The security posture is strong with HTTPS enforced and no visible vulnerabilities, but the absence of explicit privacy policies and contact information for security incidents suggests room for improvement in transparency and compliance. Overall, the website reflects a high level of professionalism and trustworthiness consistent with a large enterprise healthcare organization.

Scanned

NIS2 and GDPR posture

GDPR outside view
88/ 100 · Low
Checks completed
7of 7

NIS2 Art. 21(2)

  1. (a) Risk analysis and security policies: Not visible from outside
  2. (b) Incident handling: One indicator
  3. (c) Business continuity, backups and crisis management: Not visible from outside
  4. (d) Supply chain security: Not visible from outside
  5. (e) Secure acquisition, development and maintenance, including vulnerability handling: Partly checked
  6. (f) Assessing the effectiveness of security measures: Not visible from outside
  7. (g) Cyber hygiene and security training: Not visible from outside
  8. (h) Cryptography and encryption: Partly checked
  9. (i) HR security, access control and asset management: One indicator
  10. (j) Multi-factor authentication and secured communications: Not visible from outside

This scan rated NIS2 with an earlier keyword method that is no longer shown; rescan for the per-article view. Risk management, continuity, supply chain, training, MFA, management oversight (Art. 20) and incident reporting (Art. 23) need internal evidence, and Guard cannot tell whether NIS2 applies to this organisation.

GDPR is indicative only, based on publicly visible signals: Articles 7, 12, 13 and 32 of Regulation (EU) 2016/679 and Article 5(3) of the ePrivacy Directive. Not a certification or legal assessment.

Priority findings

2 findings rated critical or high. Fix these first.

  1. SSL/TLS

    TLS encrypts the connection and proves the site is really yours. Weak or expiring certificates trigger browser warnings and put traffic at risk.

    • High

      Weak Protocols Supported

      Server supports weak protocols: TLSv1.1

      What to do: Disable TLS 1.0, TLS 1.1, and all SSL versions

      • CWE-327
      • OWASP A04:2025
      • ASVS V12.1.1
    • High

      Weak SSL Key Length

      SSL certificate uses 256-bit key, which is considered weak

      What to do: Use at least 2048-bit RSA or 256-bit ECC key

      • CWE-326
      • OWASP A04:2025
      • Mozilla TLS: Mozilla Server Side TLS 6.0 intermediate: rsa_key_size 2048

Need hands-on remediation? Email guard@offseq.com

Keep watching janssen.com

This scan found 16 issues across 6 checks. Monitoring re-runs those checks daily, emails you when something material changes and records each fix, so you can show progress.

Daily monitoring

Recommended

€25per month

  • TLS certificates and expiry
  • DNS records
  • SPF, DKIM and DMARC
  • Security headers
  • GDPR and NIS2 posture
  • Exposed services
  • Third-party trackers
  • Security score drift

Email alerts on material changes and an exportable JSON history of every change.

Billed monthly to your card. Cancel anytime. See sample alerts.

Full report

€39.90one-time

  • The complete analysis as a PDF you can cite
  • Email delivery with an unlock code
  • Lifetime access to this report

Prices incl. 21% VAT. Secure checkout by Mollie; sold by SEQ SIA, Latvia.

Results by check

Each check with its score, findings and the evidence it collected.

How this score is calculated

The security score runs 0–100, higher is better. It is the plain average of the security checks that completed in this scan, each counted equally. A check that could not run is left out: it counts neither as a pass nor as a fail.

Counted in this score

SSL/TLS
57
Security headers
80
Email security
70
DNS health
85
Network security
100
GDPR outside view
88
Average
80

Not counted

  • NIS2 outside view: Re-weights evidence from the TLS, email, DNS, network and hygiene checks, so counting it would count that evidence twice. Shown on its own.
  • OffSeq Observations: An AI reading of the site, useful context but not reproducible evidence. Shown on its own.

Findings that cap the score at 49

Each of these is serious on its own, so while any is present the site cannot rate better than high risk, however good the other checks are.

  • The certificate is not trusted by browsers
  • The website is not served over HTTPS
  • A database, remote desktop, file-sharing or Telnet service is reachable from the internet
  • The page loads a script from a compromised source
  • The domain registration has expired
  • SPF authorises every server to send mail as the domain

Partial scans

When the site blocks Guard or most checks cannot run, the score covers only the checks that ran (usually DNS and email), is capped at 75 and is shown as partial, without a risk level.

Risk levels

  • Critical0–25
  • High26–49
  • Medium50–75
  • Low76–100

Technical appendix

Business context, site observations and technical notes gathered during the scan, and the standards behind each reference.

Business context

Business profile

Johnson & Johnson Innovative Medicine operates within the healthcare sector as part of a large enterprise. The business model centers on pharmaceutical innovation and medicine development, targeting healthcare professionals and patients. The company benefits from strong brand recognition and a global footprint. The website's content and structure indicate a focus on research and development, with no direct e-commerce or sales functions visible. The use of Brightspot CMS and integration with major analytics and consent tools suggests a well-resourced digital strategy. The lack of visible contact details or detailed corporate information on the page may reflect a controlled communication approach typical of large corporations. No suspicious or unrelated domains are linked, reinforcing the site's legitimacy.

Security posture

The website employs HTTPS and integrates a cookie consent mechanism, indicating compliance with basic security and privacy standards. However, explicit security headers such as Content-Security-Policy or X-Frame-Options are not evident in the provided content, which could enhance protection against common web attacks. No exposed sensitive data or vulnerable libraries were detected. The absence of a published security policy, incident response contacts, or vulnerability disclosure program limits transparency and may hinder rapid response to security incidents. Overall, the security posture is solid but could be improved by adding explicit security headers and publicly accessible security documentation.

Recommendations

  1. Implement and publish explicit security headers like Content-Security-Policy and X-Frame-Options to enhance protection.
  2. Add a clear privacy policy page linked prominently on the website to improve privacy compliance transparency.
  3. Provide contact information or a dedicated security page for incident reporting and vulnerability disclosures.
  4. Consider publishing a security.txt file to facilitate responsible vulnerability reporting.
  5. Enhance visibility of business contact details to improve user trust and support.
Site observations

Automated reading of the public site. Ratings are indicative.

Business

Company
Innovative Medicine Global
Description
Johnson & Johnson Innovative Medicine is a global healthcare business focused on developing innovative medicines. The website presents information about their research, development, and commitment to advancing healthcare solutions.
Key services
Pharmaceutical research, Innovative medicine development, Healthcare solutions
Content quality
good
Branding
consistent

Technology

Stack
JavaScript, Google Tag Manager, OneTrust Cookie Consent, WebComponents polyfill, Brightspot CMS assets
Performance
moderate
Mobile
good
Accessibility
good
SEO
good

Security

Observed score
85/100
Good practices seen
  • HTTPS enforced
  • Cookie consent banner implemented
  • No exposed sensitive data in HTML

Analytics and tracking

Services
Google Tag Manager
Tracking level
moderate
Privacy practices
good

Advertising

Transparency
basic

Site quality

Design
good
User experience
good
Content relevance
good
Navigation
good
Professionalism
excellent
Trustworthiness
high

Key observations

  1. Website is fully accessible with no blocking or WAF challenges.
  2. Content is professional and relevant to healthcare and pharmaceutical innovation.
  3. Cookie consent mechanism is implemented with OneTrust.
  4. No explicit contact emails or phone numbers found on the page.
  5. WHOIS data is unavailable, likely due to privacy or registry restrictions.
  6. Use of modern web fonts and polyfills indicates attention to cross-browser compatibility.
  7. Google Tag Manager is used for analytics and tracking.
  8. No visible security.txt or vulnerability disclosure page.
  9. No explicit privacy policy or terms of service links found in the provided content snippet.
Technical notes

Notes

The website uses modern web fonts hosted on Brightspot CDN and Google Fonts, with polyfills for legacy browser support, indicating attention to cross-browser compatibility. Google Tag Manager is used for analytics and tracking, integrated asynchronously for performance. The site is built on the Brightspot CMS platform, a professional content management system suitable for enterprise needs. Performance appears moderate with optimized assets, and mobile optimization is good. Accessibility features such as skip links and ARIA roles are present, supporting inclusive design. SEO is supported by proper meta tags, Open Graph data, and JSON-LD structured data describing the organization and website. No major technical debt or outdated technologies were detected in the provided content.
Standards and sources

Reference chips under each finding point to the standard, regulation or specification the finding relates to. They are taken from the official datasets below and mapped conservatively: a finding with no defensible link shows none. NIS2 and GDPR references mark where a finding is relevant evidence, not a compliance verdict. Implementing Regulation (EU) 2024/2690 binds digital infrastructure and digital service providers; for other entities it is the most detailed public reading of the Article 21 measures. WCAG, EN 301 549, European Accessibility Act and Web Accessibility Directive references name the requirement an automated accessibility rule relates to; they are not a conformance verdict.

Retrieved 2026-10-25

Earlier scans of this domain

  1. 83/100 +25Low22 findingsView report
  2. 58/100Medium21 findingsView report
Reviews of this site

Share your experience with janssen.com. Every review is verified by email and published after moderation.

Overall rating
Select a rating
4000 characters remaining

We’ll email you to confirm your review and keep your details private.

Community rating

No published reviews yet. Be the first to review janssen.com.

Feedback on this report

Rate this report, add an optional comment, and tell us if you want a security specialist to follow up.

Overall report quality
Select a rating
2000 characters remaining

We only use your feedback to improve Guard reports. Contact details are never shared.